JP2017514856A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514856A5
JP2017514856A5 JP2016566651A JP2016566651A JP2017514856A5 JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5 JP 2016566651 A JP2016566651 A JP 2016566651A JP 2016566651 A JP2016566651 A JP 2016566651A JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
alkoxy
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514856A (ja
JP6483156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029409 external-priority patent/WO2015171722A1/en
Publication of JP2017514856A publication Critical patent/JP2017514856A/ja
Publication of JP2017514856A5 publication Critical patent/JP2017514856A5/ja
Application granted granted Critical
Publication of JP6483156B2 publication Critical patent/JP6483156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566651A 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ Active JP6483156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
US61/989,651 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (3)

Publication Number Publication Date
JP2017514856A JP2017514856A (ja) 2017-06-08
JP2017514856A5 true JP2017514856A5 (2) 2018-04-19
JP6483156B2 JP6483156B2 (ja) 2019-03-13

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566651A Active JP6483156B2 (ja) 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ

Country Status (33)

Country Link
US (4) US9873679B2 (2)
EP (1) EP3140296B1 (2)
JP (1) JP6483156B2 (2)
KR (1) KR102336370B1 (2)
CN (1) CN106458976B (2)
AR (1) AR100328A1 (2)
AU (1) AU2015256120B2 (2)
BR (1) BR112016024936A2 (2)
CA (1) CA2948161C (2)
CL (1) CL2016002809A1 (2)
CY (1) CY1120340T1 (2)
DK (1) DK3140296T3 (2)
EA (1) EA033250B1 (2)
ES (1) ES2674531T3 (2)
HR (1) HRP20180641T1 (2)
HU (1) HUE039288T2 (2)
IL (1) IL248668B (2)
MA (1) MA39427B1 (2)
MX (1) MX378160B (2)
MY (1) MY181959A (2)
NZ (1) NZ727146A (2)
PE (1) PE20161363A1 (2)
PH (1) PH12016502034B1 (2)
PL (1) PL3140296T3 (2)
PT (1) PT3140296T (2)
RS (1) RS57170B1 (2)
SG (1) SG11201609170UA (2)
SI (1) SI3140296T1 (2)
SM (1) SMT201800342T1 (2)
TN (1) TN2016000444A1 (2)
TR (1) TR201809633T4 (2)
TW (1) TWI659951B (2)
WO (1) WO2015171722A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256038B2 (en) * 2014-05-07 2019-07-11 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
DK3140296T3 (en) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
JPWO2018181847A1 (ja) * 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN110772636B (zh) * 2017-08-21 2021-03-16 武汉大学 Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
KR20120104534A (ko) * 2009-10-06 2012-09-21 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 gpr40 조절제
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
EP2880034B1 (en) 2012-08-01 2016-06-22 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
CA2891535A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
BR112015010649A2 (pt) * 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina
WO2014078610A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
JP6322204B2 (ja) 2012-11-16 2018-05-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ジヒドロピラゾールのgpr40モジュレーター
DK3140296T3 (en) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
US10301260B2 (en) 2014-05-07 2019-05-28 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
CN106456536B (zh) 2014-05-07 2020-05-12 克罗马药品股份有限公司 水性眼用溶液和治疗干眼综合征的方法

Similar Documents

Publication Publication Date Title
JP2017514856A5 (2)
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP7611278B2 (ja) 金属酵素阻害剤化合物
JP2018505203A5 (2)
JP6055150B1 (ja) Apj受容体のトリアゾールアゴニスト
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2017508794A5 (2)
JP2016516043A5 (2)
JP2024514010A (ja) カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP2016520128A5 (2)
JP2015500887A5 (2)
JP2017508795A5 (2)
JP2017529389A5 (2)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2016526576A5 (2)
JP2016525136A5 (2)
JP2017514865A5 (2)
JP2013518110A (ja) 疼痛および他の適応症の治療用の医薬組成物
WO2011074658A1 (ja) 新規抗血小板薬
WO2010122980A1 (ja) 新規甲状腺ホルモンβ受容体作動薬
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2016513696A5 (2)
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
JP2016513681A5 (2)
JP2013523814A5 (2)